Novel small molecules for the treatment of infections caused by Candida albicans: A patent review (2002 - 2010)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 3, 2011, Pages 381-397

  Calugi, Chiara ^a   Trabocchi, Andrea ^a   Guarna, Antonio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

aspartyl proteases; azoles; drug resistance; echinocandin; fungal infections; glucan synthase; peptidomimetics; polyenes

Indexed keywords

AMINOCANDIN; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ASPARTIC PROTEINASE INHIBITOR; CASPOFUNGIN; CHITIN SYNTHASE INHIBITOR; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FR 290581; GLUCAN SYNTHASE INHIBITOR; GLYCOSYLTRANSFERASE INHIBITOR; ITRACONAZOLE; MANNOSYLTRANSFERASE INHIBITOR; MICAFUNGIN; MORINIAFUNGIN; NATAMYCIN; NATURAL PRODUCT; NIKKOMYCIN Z; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POLYPEPTIDE ANTIBIOTIC AGENT; POSACONAZOLE; SCH 57404; SORDARIN DERIVATIVE; TERBINAFINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE; ZOFIMARIN;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; CANDIDA ALBICANS; CANDIDIASIS; COCCIDIOIDOMYCOSIS; DERMATOPHYTOSIS; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; NEPHROTOXICITY; NONHUMAN; PATENT; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; ASPARTIC ACID ENDOPEPTIDASES; CANDIDIASIS; CHITIN SYNTHASE; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; HUMANS; INDENES; MANNOSYLTRANSFERASES; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79952049866     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.551116     Document Type: Review

References (102)

1. Marr KA. Fungal infections in oncology patients: update of epidemiology, prevention, and treatment. Curr Opin Oncol 2009;22:138-42
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63 (Pubitemid 46167771)
3. Wisplinghoff H, Bischoff T, Tallent SM, et al Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17 (Pubitemid 39050477)
4. Sims CR, Ostrosky-Zeichner L, Rex JH. Invasive candidiasis in immunocompromised hospitalized patients. Arch Med Res 2005;36:660-71 (Pubitemid 41436235)
5. Mishra NN, Prasad T, Sharma N, et al Pathogenicity and drug resistance in Candida albicans and other yeast species. A review. Acta Microbiol Immunol Hungarica 2007;54:201-35 (Pubitemid 47364462)
6. Hube B. From commensal to pathogen: stage- and tissue-specific gene expression of Candida albicans. Curr Opin Microbiol 2004;7:336-41 (Pubitemid 39091116)
7. Calderone RA, Fonzi WA. Virulence factors of Candida albicans. Trends Microbiol 2001;9:327-35 (Pubitemid 32575277)
8. Gruszecki WI, Gagos M, Herec M, Kernen P. Organization of antibiotic amphotericin B in model lipid membranes. A mini review. Cell Mol Biol Lett 2003;8:161-70 (Pubitemid 36534578)
9. Ostrosky-Zeichner L. Casadevall A, Galgiani JN, Odds FC, Rex JH. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010;9:719-27
10. Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother 2000;12:463-70 (Pubitemid 32048160)
11. Jung SH, Lim DH, Jung SH, et al Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur J Pharm Sci 2009;37:313-20
12. Zarif L, Graybill JR, Perlin D, et al Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. Antimicrob Agents Chemother 2000;44:1463-9 (Pubitemid 30340780)
13. Akins RA. An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol 2005;43:285-318 (Pubitemid 41030457)
14. Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manage 2005;1:299-306
15. Ortonne P, Korting HC, Viguie-Vallanet C, et al Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athletes foot): a randomized, double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 2006;20:1307-13 (Pubitemid 44614633)
16. Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51 (Pubitemid 37222342)
17. Ghannoum MA, Kim HG, Long L. Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis. J Antimicrob Chemother 2007;59:556-9 (Pubitemid 47073466)
18. Liu G, Tian Y, Yang H, Tan H. A pathway-specific transcriptional regulatory gene for nikkomycin biosynthesis in Streptomyces ansochromogenes, that also influences colony development. Mol Microbiol 2005;55:1855-66 (Pubitemid 40445218)
19. Mohrle V, Roos U, Bormann C. Identification of cellular proteins involved in nikkomycin production in Streptomyces tendae Tu901. Mol Microbiol 1995;15:561-71
20. Nix DE, Swezey RR, Hector R, Galgiani JN. Pharmacokinetics of nikkomycin Z after single rising oral doses. Antimicrob Agents Chemother 2009;53:2517-21
21. Sandovsky-Losica H, Shwartzman R, Lahat Y, Segal E. Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B. J Antimicrob Chemother 2008;62:635-7
22. Ganesan LT, Manavathu EK, Cutright JL, et al In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus. Clin Microbiol Infect 2004;10:961-6 (Pubitemid 39562462)
23. Hauser D, Sigg HP. Isolierung und Abbau von Sordarin.1. Mitteilung uber Sordarin. Helv Chim Acta 1971;54:1178-90
24. Justice MC, Hsu M, Tse B, et al Elongation factor 2 as a novel target for selective inhibition of fungal protein synthesis. J Biol Chem 1998;273:3148-51 (Pubitemid 28109721)
25. Dominiguez JM, Martin JJ. Identification of elongation factor 2 as the essentialprotein targeted by sordarins in Candida albicans. Antimicrob Agents Chemother 1998;42:2279-83 (Pubitemid 28420364)
26. Gargallo-Viola D. Sordarins as antifungal compounds. Curr Opin Anti-infect Investig Drugs 1999;1:297-305
27. Jpn Kokai Tokkyo koho. Antibiotic Zofimarin. JP6240292; 1987
28. Banyu Seiyaku KK. Antifungal substance BE-31405. JP6157582; 1994
29. Coval SJ, Puar MS, Phife DW, et al SCH57404, an antifungal agent possessing the rare sodaricin skeleton and a tricyclic sugar moiety. J Antibiot 1995;48:1171-2
30. Merck & Co., Inc. A novel sordarin derivative isolated from culture fermentations and functions as antifungal agents. WO051889; 2003
31. Basilio A, Justice M, Harris G, et al Bioorg. The discovery of moriniafungin, a novel sordarin derivative produced by Morinia pestalozzioides. Med Chem 2006;14:560-6 (Pubitemid 41767616)
32. Kamai Y, KakutaM, Shibayama T, et al Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice. Antimicrob Agents Chemother 2005;49:52-6 (Pubitemid 40065772)
33. Hanadate T, Tomishima M, Shiraishi N, et al FR290581, a novel sordarin derivative: synthesis and antifungal activity. Bioorg Med Chem Lett 2009;19:1465-8
34. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000;46:171-9 (Pubitemid 30639285)
35. Gauwerky K, Borelli C, Korting HC. Targeting virulence: a new paradigm for antifungals. Drug Discov Today 2009;14:214-22
36. Alksne LE, Projan SJ. Bacterial virulence as a target for antimicrobial chemotherapy. Curr Opin Biotechnol 2000;11:625-36
37. Alekshun MN, Levy SB. Targeting virulence to prevent infection: to kill or not to kill? Drug Discov Today Therap Strat 2004;1:483-9 (Pubitemid 40197595)
38. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003;67:400-28 (Pubitemid 37122527)
39. Ollert MW, Wende C, Gorlich M, et al Increased expression of Candida albicans secretory proteinase, a virulence factor, in isolates from human immunodeficiency virus-positive patients. J Clin Microbiol 1995;33:2543-9
40. Wu T, Wright K, Hurst SF, Morrison CJ. Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole. Antimicrob Agents Chemother 2000;44:1200-8 (Pubitemid 30228295)
41. Navarathna DH, Hornby JM, Hoerrmann N, et al Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis. J Antimicrob Chemother 2005;56:1156-9 (Pubitemid 43009840)
42. Korting HC, Schaller M, Eder G, et al Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinase of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother 1999;43:2038-42 (Pubitemid 29395205)
43. Abad-Zapatero C, Goldman R, Muchmore SW, et al Strcture of secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents. Protein Sci 1996;5:640-52 (Pubitemid 26119701)
44. Viviani MA, De Marie S, Graybill JR, et al New approaches to antifungal chemotherapy. Med Mycol 1998;36:194-206
45. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002;50:243-60 (Pubitemid 37554852)
46. Kelly SL, Lamb DC, Kelly DE, et al Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta 5,6-desaturation. FEBS Lett 1997;400:80-2 (Pubitemid 27046825)
47. Barker KS, Crisp S, Wiederhold N, et al Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. J Antimicrob Chemother 2004;54:376-85 (Pubitemid 39177457)
48. Shangai Institute of Pharmaceutical Industry. Polyene diester antibiotics. WO015541; 2009
49. Johnson EM, Warnock DW, Luker J, et al Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 1995;35:103-14
50. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;38:1-8
51. Aventis Pharma S.A. Novel azole or triazole derivatives, method for preparing the same and use thereof as fungicides. WO006436; 2003
52. Ranbaxy Laboratories Ltd. Azole compounds as anti-fungal agents. WO008391; 2003
53. FDC Ltd. 1,2,4-Triazol-1-yl-propan-2-ol derivatives as anti-fungal agents. WO068142; 2003
54. Italfarmaco S.p.A. Azole derivatives useful as antifungal agents with reduced interaction with metabolic cytochromes. WO040156; 2005
55. Daewoong Pharmaceutical Co. Ltd. Antifungal triazole derivatives. WO109933; 2006
56. Daewoong Pharmaceutical Co. Ltd. Novel antifungal triazole derivatives. WO052943; 2007
57. Council of Scientific & Industrial Research. Antifungal compounds containing benzothiazinone, benzoxazinone or benzoxazolinone and process thereof. WO046931; 2010
58. Ruiz-Herrera J, San-Blas G. Chitin synthesis as target for antifungal drugs. Curr Drug Targets Infect Disord 2003;3:77-91 (Pubitemid 36304949)
59. Pang JY, Qin Y, Chen WH, et al Synthesis and DNA-binding affinities of monomodified berberines. Bioorg Med Chem 2005;13:5835-40 (Pubitemid 41247768)
60. Korea Research Institute of Bioscience and Biotechnology. Berberrubine derivatives having antifungal activity. WO094548; 2007
61. Park KD, Lee JH, Kim SH, et al Synthesis of 13-(substituted benzyl) berberine and berberrubine derivatives as antifungal agents. Bioorg Med Chem Lett 2006;16:3913-16 (Pubitemid 43903228)
62. Douglas CM. Fungal beta(1,3)-D-glucan synthesis. Med Mycol 2001;39(Suppl 1):55-66
63. Liu J, Balasubramanian MK. 1,3-beta-Glucan synthase: a useful target for antifungal drugs. Curr Drug Targets Infect Disord 2001;1:159-69
64. Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 2003;12:1313-33
65. Fujisawa pharmaceutical collab. Antifungal cyclic lipopeptides. WO005463; 2005
66. Astellas Pharma, Inc. Polypeptide compounds. EP2204379; 2010
67. UCB Pharma S.A. Substituted aniline derivatives. WO012524; 2008
68. Schering Corp. Pyridazinone derivatives useful as glucan synthase inhibitors. WO115381; 2008
69. Barbaro R, Betti L, Botta M, et al Synthesis, biological evaluation, and pharmacophore generation of new pyridazinone derivatives with affinity toward alpha(1)- and alpha(2)-adrenoceptors. J Med Chem 2001;44:2118-32 (Pubitemid 32861772)
70. Sonmez M, Berber I, Akbas E. Synthesis, antibacterial and antifungal activity of some new pyridazinone metal complexes. Eur J Med Chem 2006;41:101-5 (Pubitemid 43276064)
71. Schering Corp. Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors. WO115385; 2008
72. Merck & Co., Inc. Antifungal agents. WO127012; 2007
73. Merck Sharp & Dohme Corp. Antifungal agents. WO019206; 2010
74. Pelaez F, Cabello A, Platas G, et al The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms. Syst Appl Microbiol 2000;23:333-43
75. Shepherd MG. Cell envelope of Candida albicans. Crit Rev Microbiol 1987;15:7-25
76. Kawakami K, Kanai K, Fujisawa T, et al Heterocyclic compounds having antifungal activity. US191395; 2007
77. Daiichi Pharmaceutical Co., Ltd. Imidazo [1,2-a] pyridine derivative. WO064422; 2003
78. Sumitomo Chemical Co., Ltd. Imidazo [1,2-a] pyrimidines and fungicide compositions containing the same. WO022850; 2003
79. Revankar GR, Matthews TR, Robins RK. Synthesis and antimicrobial activity of certain imidazo [1,2-a] pyrimidines. J Med Chem 1975;18:1253-5
80. Buurman ET, Westwater C, Hube B, et al Molecular analysis of CaMnt1p, a mannosyl transferase important for adhesion and virulence of Candida albicans. Proc Natl Acad Sci USA 1998;95:7670-5 (Pubitemid 28293311)
81. Arroyo-Flores BL, Rodriguez-Bonilla J, Villagomez-Castro JC, et al Biosynthesis of glycoproteins in Candida albicans: activity of mannosyl and glucosyl transferases. Fungal Genet Biol 2000;30:127-33
82. Strahl-Bolsinger S, Gentzsch M, Tanner W. Protein O-mannosylation. Biochim Biophys Acta 1999;1426:297-307
83. Oxford Glycosciences (UK) Ltd. Benzylidene thiazolidinediones and their use as antimycotic agents. WO070239; 2003
84. Orchard MG, Neuss JC, Galley CM, et al Rhodanine-3-acetic acid derivatives as inhibitors of fungal protein mannosyl transferase 1 (PMT1). Bioorg Med Chem Lett 2004;14:3975-8 (Pubitemid 38844408)
85. Bristol-Myers Squibb Co. Novel thio-derivatives of sordarin as antifungal agents. WO22567; 2002
86. Merck & Co., Inc. Antifungal agents of sordarin derivatives. WO0007878; 2003
87. Merck & Co., Inc. 11-hydroxysordarin and a process for producing it using Actinomyces ssp. US6228622; 2001
88. Astellas Pharma, Inc. Sordarin derivatives for preventing or treating infectious diseases caused by pathogenic microorganisms. WO131246; 2009
89. Stewart K, Abad-Zapatero C. Candida proteases and their inhibition: prospects for antifungal therapy. Curr Med Chem 2001;8:941-8 (Pubitemid 32633552)
90. Bein M, Schaller M, Korting HC. The secreted aspartic proteinases as a new target in the therapy of candidiasis. Curr Drug Targets 2002;3:351-7
91. Cassone A, De Bernardis F, Mondello F, et al Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis 1987;156:777-83 (Pubitemid 17157428)
92. Freie Universitat Berlin. Pepstatin A derivatives. WO133188; 2009
93. Universita degli Studi di Firenze, Istituto Superiore di Sanita. Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases. WO060904; 2010
94. Trabocchi A, Mannino C, Machetti F, et al Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds. J Med Chem 2010;53:2502-9
95. Giuliani A, Pirri G, Nicoletto SF. Antimicrobial peptides: an overview of a promising class of therapeutics. Cent Eur J Biol 2007;2:1-33 (Pubitemid 46450753)
96. Zhang LJ, Falla TJ. Antimicrobial peptides: therapeutic potential. Expert Opin Pharmacother 2006;7:653-63
97. Guani-Guerra E, Santos Mendoza T, Lugo-Reyes SO, Teran LM. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol2010;135:1-11
98. C3 Jian, Inc. Antibacterial and antifungal peptides. WO080836; 2010
99. The Board of Regents of the University of Oklahoma. Antifungal peptides and methods of use thereof. WO016593; 2007
100. Shafer WM, Martin LE, Spitznagel JK. Cationic antimicrobial proteins isolated from human neutrophil granulocytes in the presence of di-isopropyl fluorophosphate. Infect Immun 1984;45:29-35 (Pubitemid 14078912)
101. Shafer WM, Martin LE, Spitznagel JK. Late intraphagosomal hydrogen ion concentration favors the in vitro antimicrobial capacity of a 37-kilodalton cationic granule protein of human neutrophil granulocytes. Infect Immun 1986;53:651-5 (Pubitemid 16053192)
102. Pereira HA, Erdem I, Pohl J, Spitznagel JK. Synthetic bactericidal peptide based on CAP37: a 37-kDa human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes. Proc Natl Acad Sci USA 1993;90:4733-7 (Pubitemid 23148980)